** Shares in Genmab GMAB.CO fall 5.4% after Johnson & Johnson JNJ.N opted out of further clinical development of the Hexabody-CD38 cancer drug on Monday
** Van Lanschot Kempen says that Hexabody did not differentiate enough from Darzalex, the company's flagship drug, and neither Genmab nor J&J will take the project forward
** While Kempen says "the shares are now free to perform" without this overhang, Jyske Bank does not expect a quick rebound but rather a slow regain of market confidence
** Kempen expects continued earnings momentum and growing appreciation for another cancer drug Epkinly as a major growth driver
** Genmab says J&J opt-out does not impact its 2025 guidance
(Reporting by Vera Dvorakova and Jesus Calero)
((vera.dvorakova@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.